Clinical research
MorphoSys AG announced that its licensing partner GSK reported in a press release earlier the start of a phase 3 clinical development program with otilimab in rheumatoid arthritis.
Even with a holiday week, July 4, there were a number of clinical trial reports. Here’s a look.
The latest clinical hold was placed after a patient experienced serious adverse events that included neurotoxicity and cytomegalovirus infection, as well as severe respiratory distress.
Genentech, a Roche company, announced that its Phase III MINISTONE-2 clinical trial hit its primary endpoint, showing that its Xofluza (baloxavir marboxil) was comparable to its own Tamiflu (oseltamivir). It was also well-tolerated in children with the flu.
Trial Designed to Test Camsirubicin Against Doxorubicin as First-Line Therapy
Companies from across the globe provide information on agreements and pipeline updates.
Pancreatic cancer is a particularly difficult cancer to treat, and although there have been advances in treatment, it is still an extremely deadly disease. Here’s a look at some recent news concerning pancreatic cancer.
Based on positive data from its FINCH program, Gilead aims to seek regulatory approval for its Jak inhibitor.
Dicerna Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced it has submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA).
Now that Novartis has a competing therapy on the market for spinal muscular atrophy (SMA), Biogen is eager to show why it thinks its Spinraza (nusinersen) is superior.
PRESS RELEASES